iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.

Memory cells, or white blood cells, from eight HIV-infected subjects with a durable viral suppression using antiretroviral therapy (HAART) were obtained and exposed in vitro to various concentrations of Oral Amp B. Samples from one patient were determined not to be susceptible to reactivation. In the remaining subjects, Oral Amp B demonstrated a reactivation response of HIV viral production in six out of seven in vitro cultures with detectable HIV reservoir. Some HIV reservoirs are not possible to reactivate and this may explain why one culture did not show reactivation response.

"There are a number of HIV latent reservoirs that are not inducible and our partners at ImmuneCarta were pleasantly surprised that six of the seven samples had inducible latent reservoirs in our study," said Dr. Peter Hnik, Chief Medical Officer of iCo Therapeutics. "By turning on expression of latent HIV proviruses, reactivation strategies such as Oral Amp B, could contribute to a reduction of HIV infection. Given these promising results, we are now evaluating the next steps in the developmental path for Oral Amp B."

SOURCE iCo Therapeutics Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Just five minutes of activity a day could reduce blood pressure